Minicircle-oriP-IFN Gamma: A Novel Targeted Gene Therapeutic System for EBV Positive Human Nasopharyngeal Carcinoma

Zuo,Kan Wu,Jun Xu,Kan Yang,Victoria C. Yan,Minghong Tan,Meng,Ying,Ming Liu,Kang,Adam Huang,Yf,Jx,. zm,Hj,Xq,Xf,Ry,Wl

2011-01-01

Abstract:National Basic Research Program of China (973 Program) [2010CB529904, 2010CB912201]; National Natural Science Foundation of Chin

What problem does this paper attempt to address?

The progress of virus-targeted new therapy against Epstein-Barr virus-associated malignancies

樊世杰,熊小龙,郑毅雄,黄凌娜,昂健

DOI: https://doi.org/10.3781/j.issn.1000-7431.2014.02.014

2014-01-01

Tumori

Abstract:The Epstein-Barr virus (EBV) has been demonstrated to be associated with several human tumors, including nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma (BL), post-transplant lymphoproliferative disease (PTLD), Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphomas (NHL) and gastric cancer (GC). In most EBV-associated malignancies, the tumor cells contain the viral genome. This provides a unique opportunity to develop therapeutic strategies utilizing the viral genome of EBV as a potential drug target. This review focuses on different therapeutic strategies against EBV-associated malignancies, further discusses the possible therapeutic approach using drug-induced virus activation and its certain pathways. DOI:10.3781/j.issn.1000-7431.2014.02.014
Data from Minicircle-IFNγ Induces Antiproliferative and Antitumoral Effects in Human Nasopharyngeal Carcinoma

Jiangxue Wu,Xia Xiao,Peng Zhao,Gang Xue,Yinghui Zhu,Xiaofeng Zhu,Limin Zheng,Yixin Zeng,Wenlin Huang

DOI: https://doi.org/10.1158/1078-0432.ccr-06-0520

IF: 13.801

2006-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: The aims of this work were to investigate the antitumor effect of IFNγ gene transfer on human nasopharyngeal carcinoma (NPC) and to assess the potential of minicircle vector for antitumor gene therapy. Experimental Design: We developed a recombinant minicircle vector carrying the human IFNγ gene and evaluated the effects of minicircle-mediated IFNγ gene transfer on NPC cell lines in vitro and on xenografts in vivo. Results: Relative to p2ΦC31-IFNγ, minicircle-mediated IFNγ gene transfer in vitro resulted in 19- to 102-fold greater IFNγ expression levels in transfected cells (293, NIH 3T3, CNE-1, CNE-2, and C666-1) and inhibited the growth of CNE-1, CNE-2, and C666-1 cells more efficiently, reducing relative growth rates to 7.1 ± 1.6%, 2.7 ± 1.0%, and 6.1 ± 1.6%, respectively. Flow cytometry and caspase-3 activity assays suggested that the antiproliferative effects of IFNγ gene transfer on NPC cell lines could be attributed to G0-G1 arrest and apoptosis. Minicircle-mediated intratumoral IFNγ expression in vivo was 11 to 14 times higher than p2ΦC31-IFNγ in CNE-2- and C666-1-xenografted mice and lasted for 21 days. Compared with p2ΦC31-IFNγ treatment, minicircle-IFNγ treatment significantly increased survival and achieved inhibition rates of 77.5% and 83%, respectively. Conclusions: Our data indicate that IFNγ gene transfer exerts antiproliferative effects on NPC cells in vitro and leads to a profound antitumor effect in vivo. Minicircle-IFNγ is more efficient than corresponding conventional plasmids due to its capability of mediating long-lasting high levels of IFNγ gene expression. Therefore, minicircle-mediated IFNγ gene transfer is a promising novel approach in the treatment of NPC.
Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

Jie-Jie Xu,Kun Yao,Chen-Jie Yu,Xi Chen,Mei-Ping Lu,Hua Sun,Bai-Zhou Li,Chuan-Ning Ding,Feng Zhou

DOI: https://doi.org/10.1016/j.anl.2006.05.019

IF: 2.119

2006-01-01

Auris Nasus Larynx

Abstract:Adoptive immunotherapy with specific cytotoxicity T lymphocytes (CTLs) induced by dendritic cells (DCs) pulsed with tumor antigens plays a crucial role in the immunity against tumor. The purpose of this study was to assess the feasibility and efficacy of latent membrane protein 2A (LMP2A)-specific CTLs immunity against nasopharyngeal carcinoma (NPC) in vitro and in vivo.DCs were generated by culturing the monocytes purified from human peripheral blood mononuclear cells (PBMCs) in cytokine cocktail containing granulocyte/macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and tumor necrosis factor-alpha (TNF-alpha). The phenotype of mature DCs was analyzed by fluorescence activated cell sorter (FACS). Mature DCs transfected with EBV-LMP2A recombinant adenovirus were co-cultured with autologous PBMCs to induce LMP2A-specific CTLs. The expression of the surface antigens such as CD3, CD4, CD8 and CD56 on CTLs were detected by FACS. The specific cytotoxicity of CTLs on target CNE cells expressing EBV-LMP2A was confirmed using cytotoxicity assay. The anti-tumor effect of LMP2A-specific CTLs in vivo was assessed in the mice tumor models implanted with CNE cells expressing EBV-LMP2A.Mature DCs expressed typically morphologic characteristics and high level of surface markers (CD1a, CD83, CD86, CD80 and HLA-DR). LMP2A-transfected DCs could induce LMP2A-specific CTLs consisting of a majority of CD4+ and CD8+ T cells. Cytotoxicity assay confirmed that the LMP2A-specific CTLs displayed significant cytotoxicity on target CNE cells compared with the controls. The study in vivo demonstrated that the treatment using these specific CTLs retarded the growth of established tumor in the treated mice.These findings suggest that DCs transfected with EBV-LMP2A recombinant adenovirus can elicit LMP2A-specific CTLs that have a specific killing effect on NPC in vitro and in vivo. The results provide experimental basis for the further immunotherapy of NPC in clinical trails.
EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models

Yanru Guo,Saidu Kamara,Jing Zhang,He Wen,Maolin Zheng,Ying Liu,Luqi Zhou,Jun Chen,Shanli Zhu,Lifang Zhang

DOI: https://doi.org/10.3389/fcimb.2022.1078504

2023-01-04

Abstract:Nasopharyngeal carcinoma (NPC), is an Epstein-Barr virus (EBV) associated malignancy most common in Southern China and Southeast Asia. In southern China, it is one of the major causes of cancer-related death. Despite improvement in radiotherapy and chemotherapy techniques, locoregional recurrence and distant metastasis remains the major causes for failure of treatment in NPC patients. Therefore, finding new specific drug targets for treatment interventions are urgently needed. Here, we report three potential ZLMP1-C affibody molecules (ZLMP1-C15, ZLMP1-C114 and ZLMP1-C277) that showed specific binding interactions for recombinant and native EBV LMP1 as determined by epitope mapping, co-localization and co-immunoprecipitation assays. The ZLMP1-C affibody molecules exhibited high antitumor effects on EBV-positive NPC cell lines and displayed minimal cytotoxicity towards EBV-negative NPC cell line. Moreover, ZLMP1-C277 showed higher antitumor efficacy than ZLMP1-C15 and ZLMP1-C114 affibody molecules. The ability of ZLMP1-C277 decrease the phosphorylation levels of up-stream activator phospho-Raf-1(Ser338), phospho-MEK1/2(Ser217/Ser221), phospho-ERK1/2(Thr202/Thr204), thereby leading to downstream suppression of phospho-p90RSK(Ser380) and transcription factor c-Fos. Importantly, tumor growth was reduced in tumor-bearing mice treated with ZLMP1-C277 and caused no apparent toxicity. Taken together, our findings provide evidence that ZLMP1-C277 as a promising therapeutic agent in EBV-associated NPC.
An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model

Chenwei Wang,Jiewen Chen,Jingyao Li,Zhihong Xu,Lihong Huang,Qian Zhao,Lei Chen,Xiaolong Liang,Hai Hu,Gang Li,Chengjie Xiong,Bin Wu,Hua You,Danyi Du,Xiaoling Wang,Hongle Li,Zibing Wang,Lin Chen

DOI: https://doi.org/10.1172/jci172092

IF: 19.456

2024-02-27

Journal of Clinical Investigation

Abstract:Adoptive transfer of T cell receptor-engineered T cells (TCR-T) is a promising strategy for immunotherapy against solid tumors. However, the potential of CD4+ T cells in mediating tumor regression has been neglected. Nasopharyngeal cancer is consistently associated with EBV. Here, to evaluate the therapeutic potential of CD4 TCR-T in nasopharyngeal cancer, we screened for CD4 TCRs recognizing EBV nuclear antigen 1 (EBNA1) presented by HLA-DP5. Using mass spectrometry, we identified EBNA1567-581, a peptide naturally processed and presented by HLA-DP5. We isolated TCR135, a CD4 TCR with high functional avidity, that can function in both CD4+ and CD8+ T cells and recognizes HLA-DP5-restricted EBNA1567-581. TCR135-transduced T cells functioned in two ways: directly killing HLA-DP5+EBNA1+ tumor cells after recognizing EBNA1 presented by tumor cells and indirectly killing HLA-DP5-negative tumor cells after recognizing EBNA1 presented by antigen-presenting cells. TCR135-transduced T cells preferentially infiltrated into the tumor microenvironment and significantly inhibited tumor growth in xenograft nasopharyngeal tumor models. Additionally, we found that 62% of nasopharyngeal cancer patients showed 50%-100% expression of HLA-DP on tumor cells, indicating that nasopharyngeal cancer is well suited for CD4 TCR-T therapy. These findings suggest that TCR135 may provide a new strategy for EBV-related nasopharyngeal cancer immunotherapy in HLA-DP5+ patients.

medicine, research & experimental
Nivolumab Treatment of Relapsed/refractory Epstein-Barr Virus–associated Hemophagocytic Lymphohistiocytosis in Adults

Pengpeng Liu,Xiangyu Pan,Chong Chen,Ting Niu,Xiao Shuai,Jian Wang,Xuelan Chen,Jiazhuo Liu,Yong Guo,Liping Xie,Yu Wu,Yu Liu,Ting Liu

DOI: https://doi.org/10.1182/blood.2019003886

IF: 20.3

2020-01-01

Blood

Abstract:Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening hyperinflammatory syndrome triggered by EBV infection. It often becomes relapsed or refractory (r/r), given that etoposide-based regimens cannot effectively clear the virus. r/r EBV-HLH is invariably lethal in adults without allogeneic hematopoietic stem cell transplantation. Here, we performed a retrospective analysis of 7 r/r EBV-HLH patients who were treated with nivolumab on a compassionate-use basis at West China Hospital. All 7 patients tolerated the treatment and 6 responded to it. Five of them achieved and remained in clinical complete remission with a median followup of 16 months (range, 11.4-18.9 months). Importantly, both plasma and cellular EBV-DNAs were completely eradicated in 4 patients. Single-cell RNA-sequencing analysis showed that HLH syndrome was associated with hyperactive monocytes/macrophages and ineffective CD8 T cells with a defective activation program. Nivolumab treatment expanded programmed death protein-1-positive T cells and restored the expression of HLH-associated degranulation and costimulatory genes in CD8 T cells. Our data suggest that nivolumab, as a monotherapy, provides a potential cure for r/r EBV-HLH, most likely by restoring a defective anti-EBV response.
EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules

Yue Liu,Ka Sin Lui,Zuodong Ye,Tsz Yan Fung,Luo Chen,Ping Yiu Sit,Chin Yu Leung,Nai Ki Mak,Ka-Leung Wong,Hong Lok Lung,Yoshimasa Tanaka,Allen Ka Loon Cheung

DOI: https://doi.org/10.7150/thno.78395

IF: 11.6

2023-01-01

Theranostics

Abstract:Nasopharyngeal carcinoma (NPC) is a diverse cancer with no well-defined tumor antigen, associated with oncogenic Epstein-Barr Virus (EBV), and with usually late-stage diagnosis and survival <40%. Current radiotherapy and chemotherapy have low effectiveness and cause adverse effects, which calls for the need of new therapy. In this regard, adoptive immunotherapy using γδ T cells has potential, but needs to be coupled with butyrophilin 2A1 and 3A1 protein expression to achieve tumoricidal effect. Methods: Human γδ T cells were expanded (with Zol or PTA) and used for cytotoxicity assay against NPC cells, which were treated with the EBV EBNA1-targeting peptide (L2)P4. Effect of (L2)P4 on BTN2A1/BTN3A1 expression in NPC cells was examined by flow cytometry and Western blot. An NPC-bearing NSG mice model was established to test the effectiveness of P4 and adoptive γδ T cells. Immunofluorescence was performed on NPC tissue sections to examine the presence of γδ T cells and expression of BTN2A1 and BTN3A1. EBV gene expression post-(L2)P4 treatment was assessed by qRT-PCR, and the relationship of LMP1, NLRC5 and BTN2A1/BTN3A1 was examined by transfection, reporter assay, Western blot, and inhibition experiments. Results: Zol- or PTA-expanded the Vδ2 subset of γδ T cells that exerted killing against certain NPC cells. (L2)P4 reactivates latent EBV, which increased BTN2A1 and BTN3A1 expression and conferred higher susceptibility towards Vδ2 T cells cytotoxicity in vitro, as well as enhanced tumor regression in vivo by adoptive transfer of Vδ2 T cells. Mechanistically, (L2)P4 induced EBV LMP1, leading to IFN-γ/p-JNK and NLRC5 activation, and subsequently stimulated the expression of BTN2A1 and BTN3A1. Conclusions: This study demonstrated the effectiveness of using the EBV-targeting probe (L2)P4 and adoptive γδ T cells as a promising combinatorial immunotherapy against NPC. The identification of the LMP1-IFN-γ/p-JNK-NLRC5-BTN2A1/BTN3A1 axis may lead to new insight and therapeutic targets against NPC and other EBV+ tumors.

medicine, research & experimental
EBV DNA methylation profiles and its application in distinguishing nasopharyngeal carcinoma and nasal NK/T-cell lymphoma

Cao-Li Tang,Xi-Zhao Li,Ting Zhou,Chang-Mi Deng,Cheng-Tao Jiang,Yu-Meng Zhang,Ying Liao,Tong-Min Wang,Yong-Qiao He,Wen-Qiong Xue,Wei-Hua Jia,Xiao-Hui Zheng

DOI: https://doi.org/10.1186/s13148-024-01624-y

2024-01-12

Clinical Epigenetics

Abstract:As an oncovirus, EBV is associated with multiple cancers, including solid tumors and hematological malignancies. EBV methylation plays an important role in regulating tumor occurrence. However, the EBV methylation profiles in EBV-associated tumor tissues are poorly understood.

oncology,genetics & heredity
EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1

Jie Wang,Junshang Ge,Yian Wang,Fang Xiong,Jiayue Guo,Xianjie Jiang,Lishen Zhang,Xiangying Deng,Zhaojian Gong,Shanshan Zhang,Qijia Yan,Yi He,Xiayu Li,Lei Shi,Can Guo,Fuyan Wang,Zheng Li,Ming Zhou,Bo Xiang,Yong Li,Wei Xiong,Zhaoyang Zeng

DOI: https://doi.org/10.1038/s41467-022-28479-2

IF: 16.6

2022-02-14

Nature Communications

Abstract:Abstract Epstein-Barr virus (EBV) is reportedly the first identified human tumor virus, and is closely related to the occurrence and development of nasopharyngeal carcinoma (NPC), gastric carcinoma (GC), and several lymphomas. PD-L1 expression is elevated in EBV-positive NPC and GC tissues; however, the specific mechanisms underlying the EBV-dependent promotion of PD-L1 expression to induce immune escape warrant clarification. EBV encodes 44 mature miRNAs. In this study, we find that EBV-miR-BART11 and EBV-miR-BART17-3p upregulate the expression of PD-L1 in EBV-associated NPC and GC. Furthermore, EBV-miR-BART11 targets FOXP1 , EBV-miR-BART17-3p targets PBRM1 , and FOXP1 and PBRM1 bind to the enhancer region of PD-L1 to inhibit its expression. Therefore, EBV-miR-BART11 and EBV-miR-BART17-3p inhibit FOXP1 and PBRM1, respectively, and enhance the transcription of PD-L1 ( CD274 , http://www.ncbi.nlm.nih.gov/gene/29126 ), resulting in the promotion of tumor immune escape, which provides insights into potential targets for EBV-related tumor immunotherapy.

multidisciplinary sciences
Establishment of a protocol for rapidly expanding Epstein-Barr-virus-specific cytotoxic T cells with enhanced cytotoxicity

Chih-Hao Fang,Ya Fang Cheng,Shian-Ren Lin,Wan-Yu Lai,Li-Ren Liao,Yen-Ling Chiu,Jan-Mou Lee

DOI: https://doi.org/10.1186/s12885-024-12707-7

IF: 4.638

2024-08-08

BMC Cancer

Abstract:Background: Lytic Epstein-Barr virus (EBV) infection plays a major role in the pathogenesis of nasopharyngeal carcinoma (NPC). For patients with recurrent or metastatic NPC and resistant to conventional therapies, adoptive cell therapy using EBV-specific cytotoxic T cells (EBV-CTLs) is a promising option. However, the long production period (around 3 to 4 weeks) and low EBV-CTL purity (approximately 40% of total CD8 T cells) in the cell product limits the application of EBV-CTLs in clinics. Thus, this study aimed to establish a protocol for the rapid production of EBV-CTLs. Methods: By culturing peripheral blood mononuclear cells (PBMCs) from EBV-seropositive donors with EBV-specific peptides and interleukin (IL)-2, IL-15, and interferon α (IFN-α) for 9 days, we identified that IL-15 can enhance IL-2-mediated CTL activation and significantly increase the yield of CTLs. Results: When IFN-α was used in IL-2/IL-15-mediated CTL production from days 0 to 6, the productivity of EBV-CTLs and EBV-specific cytotoxicity significantly were reinforced relative to EBV-CTLs from IL-2/IL-15 treatment. Additionally, IFN-α-induced production improvement of virus-specific CTLs was not only the case for EBV-CTLs but also for cytomegalovirus-specific CTLs. Conclusion: We established a novel protocol to rapidly expand highly pure EBV-CTLs from PBMCs, which can produce EBV-CTLs in 9 days and does not require feeder cells during cultivation.
Identification of HLA-A*11:01 and A*02:01-Restricted EBV Peptides Using HLA Peptidomics

Yufei Wang,Wanlin Zhang,Ruona Shi,Yanran Luo,Zhenhuan Feng,Yanhong Chen,Qiuting Zhang,Yan Zhou,Jingtong Liang,Xiaoping Ye,Qisheng Feng,Xiaofei Zhang,Miao Xu

DOI: https://doi.org/10.3390/v16050669

2024-04-26

Viruses

Abstract:Epstein-Barr Virus (EBV) is closely linked to nasopharyngeal carcinoma (NPC), notably prevalent in southern China. Although type II latency of EBV plays a crucial role in the development of NPC, some lytic genes and intermittent reactivation are also critical for viral propagation and tumor progression. Since T cell-mediated immunity is effective in targeted killing of EBV-positive cells, it is important to identify EBV-derived peptides presented by highly prevalent human leukocyte antigen class I (HLA-I) molecules throughout the EBV life cycle. Here, we constructed an EBV-positive NPC cell model to evaluate the presentation of EBV lytic phase peptides on streptavidin-tagged specific HLA-I molecules. Utilizing a mass spectrometry (LC-MS/MS)-based immunopeptidomic approach, we characterized eleven novel EBV peptides as well as two previously identified peptides. Furthermore, we determined these peptides were immunogenic and could stimulate PBMCs from EBV VCA/NA-IgA positive donors in an NPC endemic southern Chinese population. Overall, this work demonstrates that highly prevalent HLA-I-specific EBV peptides can be captured and functionally presented to elicit immune responses in an in vitro model, which provides insight into the epitopes presented during EBV lytic cycle and reactivation. It expands the range of viral targets for potential NPC early diagnosis and treatment.

virology
TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.

Qingzhu Jia,Ling Peng,Gang Chen,Haiyang Wu,Dong Zeng,Tao Liu,Yunpeng Zhan,Si Li,Frank Su,Bo Zhu,Qi-Jing Li

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.6047

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:6047 Background: Nasopharyngeal carcinoma (NPC) refraction and metastasis is common, but therapeutics are limited. As adoptive immunotherapy has emerged as effective against other cancers, engineered T cells bearing a transgenic Epstein-Barr virus (EBV)-specific TCR (TCR-T) represent a viable approach to treat EBV-associated NPC. Given PD-1/PD-L1 induced T cell hypofunction, we herein report preliminary findings of a phase I trial of EBV-targeting TCR-T cells armored with secreted PD-1 blockade for patients who failed in two or more lines of standard therapies. Methods: Patients with advanced NPCs were consented and screened for EBV serotype and HLA haplotype. EBV+/HLA-A*02+ patients were enrolled in a rapid titration setting to escalate the single infusion dose from 5x10 6 to 1.0x10 7 and 5.0x10 7 /kg TCR-T cells. After safety evaluation, the 5.0X10 7 /kg cohort was expanded for further investigation of combining with IL-2 administration. Fludarabine/cyclophosphamide were administered prior to TCR-T cell transfer as pre-conditioning. Patient monitoring and peripheral blood analysis occurred weekly over the first month and then monthly until disease progression or patient withdrawal. The primary objective was to determine safety and a recommended phase 2 dose (RP2D), while the secondary objective was investigator assessed ORR (RECIST v1.1). Results: One patient per TCR-T dose was treated, and, as no dose-limiting toxicity (DLT) has been observed, dose level 3 (5.0x10 7 /kg) was expanded with IL-2 administration upon TCR-T cell infusion. As of January 2023, six patients have been treated. One patient (16.7%) exhibited grade 1 CRS (n=6). No grade 4 treatment-related adverse events (TRAEs) have been observed, with leukopenia and fever being the most common AEs. Two patients (33.3%) were assessed as partial response (PR), with one reaching a response duration of 9 months to date. Three patients (50%) were assessed as stable disease (SD). For all patients, pharmacokinetic analysis revealed that levels of TCR-T cells in peripheral blood peak between 3- and 14-days post-infusion, with a maximum duration of 180 days. Conclusions: EBV-targeting TCR-T cells armored with PD-1 blockade are well tolerated. Initial results from this ongoing study indicate that EBV proteins may be safe and effective TCR-T targets to achieve superior outcomes in advanced EBV-positive NPC patients. Clinical trial information: NCT04139057 . [Table: see text]

oncology
Adenovirus-mediated Delivery of Interferon-Γ Gene Inhibits the Growth of Nasopharyngeal Carcinoma

Ran-yi Liu,Ying-hui Zhu,Ling Zhou,Peng Zhao,Hong-li Li,Lan-cai Zhu,Hong-yu Han,Huan-xin Lin,Liang Kang,Jiang-xue Wu,Wenlin Huang

DOI: https://doi.org/10.1186/1479-5876-10-256

IF: 8.44

2012-01-01

Journal of Translational Medicine

Abstract:Background Interferon-γ (IFN-γ) is regarded as a potent antitumor agent, but its clinical application is limited by its short half-life and significant side effects. In this paper, we tried to develop IFN-γ gene therapy by a replication defective adenovirus encoding the human IFN-γ (Ad-IFNγ), and evaluate the antitumoral effects of Ad-IFNγ on nasopharyngeal carcinoma (NPC) cell lines in vitro and in xenografts model. Methods The mRNA levels of human IFN-γ in Ad-IFNγ-infected NPC cells were detected by reverse transcription-polymerase chain reaction (RT-PCR), and IFN-γ protein concentrations were measured by enzyme-linked immunosorbent assay (ELISA) in the culture supernatants of NPC cells and tumor tissues and bloods of nude mice treated with Ad-IFNγ. The effects of Ad-IFNγ on NPC cell proliferation was determined using MTT assay, cell cycle distribution was determined by flow cytometry analysis for DNA content, and cells apoptosis were analyzed by Annexin V-FITC/7-AAD binding assay and hoechst 33342/PI double staining. The anti-tumor effects and toxicity of Ad-IFNγ were evaluated in BALB/c nude mice carrying NPC xenografts. Results The results demonstrated that Ad-IFNγ efficiently expressed human IFN-γ protein in NPC cell lines in vitro and in vivo . Ad-IFNγ infection resulted in antiproliferative effects on NPC cells by inducing G1 phase arrest and cell apoptosis. Intratumoral administration of Ad-IFNγ significantly inhibited the growth of CNE-2 and C666-1 cell xenografts in nude mice, while no significant toxicity was observed. Conclusions These findings indicate IFN-γ gene therapy mediated by replication defective adenoviral vector is likely a promising approach in the treatment of nasopharyngeal carcinoma.
Preclinical study of LMP1-RNAi-based anti-tumor therapy in EBV-positive nasopharyngeal carcinoma

Qi Yuan,Bing-Hong Chen,Dai-Jia Huang,Rong Zhang

DOI: https://doi.org/10.1590/1414-431X2023e12638

2023-07-21

Abstract:RNA interference (RNAi) treatment has been proven to be an important therapeutic approach in cancer based on downregulation of target-oncogenes, but its clinical efficacy still needs further investigation. LMP1 is usually presented by Epstein-Barr virus (EBV)-positive tumor cells like EBV-associated nasopharyngeal carcinoma (NPC) and acts as an oncogene in tumorigenesis. However, the mechanism of LMP1 as a proto-oncogene in nasopharyngeal carcinoma is still unclear. Two sequence-specific shRNAs 1 and 2 were designed to target the different nucleotide loci of EBV latent antigen LMP1 gene and a series of in vivo and in vitro experiments were performed to investigate the therapeutic effect of sequence-specific shRNAs targeting LMP1 and its related molecular mechanisms in EBV-positive NPC. LMP1-shRNA2 generated a truncated LMP1 mRNA and protein, whereas LMP1-shRNA1 completely blocked LMP1 mRNA and protein expression. Both LMP1-shRNAs inhibited the proliferation and migration of NPC cells overexpressing LMP1 (NPC-LMP1) as well as the NPC-associated myeloid-derived suppressor cell (MDSC) expansion in vitro. However, LMP1-shRNA2 maintained the immunogenicity of NPC-LMP1 cells, which provoked MHC-class I-dependent T cell recognition. LMP1-shRNAs inhibited tumor growth in nude mice but did not reach statistical significance compared to control groups, while the LDH nanoparticle loaded LMP1-shRNAs and the antigen-specific T cells induced by NPC-LMP1 cells treated with LMP1-shRNA2 significantly reduced tumor growth in vivo. LMP1-RNAi-based anti-tumor therapy could be a new hope for the clinical efficacy of RNAi treatment of tumors like NPC.
Structure-based design of antibodies targeting the EBNA1 DNA-binding domain to block Epstein-Barr virus latent infection and tumor growth

Yongyue Han,Fang Wu,Ying Zhang,Jun Liu,Yuzhe Wu,Yuecheng Wang,Xiwen Jiang,Xin Chen,Wei Xu

DOI: https://doi.org/10.1002/mco2.739

2024-10-10

Abstract:The Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is critically involved in maintaining episomes during latent infection and promoting tumorigenesis. The development of an epitope-specific monoclonal antibody (mAb) for EBNA1 holds great promise due to its high affinity and specificity, offering a new and innovative approach for the treatment of EBV-related diseases. In this proof-of-concept study, we employed a structure-based design strategy to create three unique immunogens specifically targeting the DNA binding state of the EBNA1 DBD. By immunizing mice, we successfully generated a mAb, named 5E2-12, which selectively targets the DNA binding interface of EBNA1. The 5E2-12 mAb effectively disrupts the interaction between EBNA1 and DNA binding, resulting in reduced proliferation of EBV-positive cells and inhibition of xenograft tumor growth in both cellular assays and mouse tumor models. These findings open up new avenues for the development of innovative biological macromolecular drugs that specifically target EBNA1 and provide potential for clinical therapy options for early-stage EBV-positive tumors. The epitope-specific mAb approach demonstrates novelty and innovation in tackling EBV-related diseases and may have broad implications for precision medicine strategies in the field of viral-associated cancers.
The emerging role of Epstein-Barr virus encoded microRNAs in nasopharyngeal carcinoma

Chunmei Fan,Yanyan Tang,Jinpeng Wang,Fang Xiong,Can Guo,Yumin Wang,Bo Xiang,Ming Zhou,Xiayu Li,Xu Wu,Yong Li,Xiaoling Li,Guiyuan Li,Wei Xiong,Zhaoyang Zeng

DOI: https://doi.org/10.7150/jca.25460

IF: 3.9

2018-01-01

Journal of Cancer

Abstract:Epstein-Barr virus (EBV) is an oncogenic herpes virus that is closely associated with the initiation and development of nasopharyngeal carcinoma (NPC), lymphoma and other malignant tumors. EBV encodes 44 mature miRNAs that regulate viral and host cell gene expression and plays a variety of roles in biological functions and the development of cancer. In this review, we summarized the biological functions and molecular mechanisms of Epstein-Barr virus-encoded microRNAs (EBV miRNAs) in tumor immune evasion, proliferation, anti-apoptosis, invasion, metastasis and as a potential biomarker for NPC diagnosis and prognosis. The knowledge generated by EBV miRNAs can be used for EBV miRNA-based precision cancer treatments in the near future.

oncology
Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody

Huixia He,Feifei Lei,Le Huang,Ke Wang,Yaxi Yang,Liu Chen,Yun Peng,Yinming Liang,Huabing Tan,Xiaoyan Wu,Mingqian Feng

DOI: https://doi.org/10.1016/j.biopha.2023.114797

Abstract:Acute and persistent infection of Epstein-Barr virus (EBV) is associated with several life-threatening hematological disorders, including lymphoproliferative disorders (LPD), hemophagocytic lymphohistiocytosis (HLH), and chronic active Epstein-Barr virus infection (CAEBV). Currently, there are no efficacious virus-targeted therapies for EBV-driven hematological diseases. To explore the potential of phagocytosis-based immunotherapy, we created a bispecific antibody by targeting the viral envelope protein gp350 with a novel EBV-neutralizing antibody (named R1) that was paired with a monoclonal antibody against CD89 for redirecting macrophages and neutrophils. In vitro study showed that the bispecific antibody enabled efficient phagocytosis of EBV and killing of gp350 + lymphoma cells in the presence of PBMC. In vivo studies in NSG mice inoculated with EBV showed that bispecific antibody dramatically reduced the viral load in blood, solid organs and tissues. Treatment of mice implanted with EBV-harboring Raji lymphoma cells efficiently prevented tumor formation and massive metastasis to solid organs. Treatment of mice implanted with whole blood from EBV-HLH patients was effective in reducing viral levels in blood and solid organ. The gp350/CD89 bispecific antibody was highly effective in clearing EBV and immunotherapy of EBV-driven hematological diseases such as LPD and EBV-HLH.
A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV

Cong Sun,Yin-Feng Kang,Xin-Yan Fang,Yi-Na Liu,Guo-Long Bu,Ao-Jie Wang,Yan Li,Qian-Ying Zhu,Hua Zhang,Chu Xie,Xiang-Wei Kong,Yong-Jian Peng,Wen-Jie Lin,Ling Zhou,Xin-Chun Chen,Zheng-Zhou Lu,Hui-Qin Xu,Dong-Chun Hong,Xiao Zhang,Ling Zhong,Guo-Kai Feng,Yi-Xin Zeng,Miao Xu,Qian Zhong,Zheng Liu,Mu-Sheng Zeng

DOI: https://doi.org/10.1016/j.chom.2023.09.011

2023-11-08

Abstract:Epstein-Barr virus (EBV) is a global public health concern, as it is known to cause multiple diseases while also being etiologically associated with a wide range of epithelial and lymphoid malignancies. Currently, there is no available prophylactic vaccine against EBV. gB is the EBV fusion protein that mediates viral membrane fusion and participates in host recognition, making it critical for EBV infection in both B cells and epithelial cells. Here, we present a gB nanoparticle, gB-I53-50 NP, that displays multiple copies of gB. Compared with the gB trimer, gB-I53-50 NP shows improved structural integrity and stability, as well as enhanced immunogenicity in mice and non-human primate (NHP) preclinical models. Immunization and passive transfer demonstrate a robust and durable protective antibody response that protects humanized mice against lethal EBV challenge. This vaccine candidate demonstrates significant potential in preventing EBV infection, providing a possible platform for developing prophylactic vaccines for EBV.
A Phase I/II Trial of CRISPR-Cas9-mediated PD-1 Knockout Epstein-Barr Virus Cytotoxic Lymphocytes (Ebv-Ctls) for Advanced Stage EBV Associated Malignancies

B. Liu,J. Yan,S. Su,J. Shao,Y. Zhao,Q. Xu,Y. Yang,Z. Zou,X. Huang,J. Wei

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.tps3118

IF: 51.769

2018-01-01

Annals of Oncology

Abstract:TPS3118Background: EBV associated malignancies exhibits high amplification of PD-L1 as distinguished from EBV non-associated malignancies (Kim et al. Gastroenterology 2015; Chen et al. Clinical Can...
Experimental Study on the Co-Application of Rta-expressing Baculovirus Vector and Ganciclovir for the Therapy of Nasopharyngeal Carcinoma

WANG Le-yao,ZHONG Peng,SHAN Liang,ZHONG Jiang

DOI: https://doi.org/10.3969/j.issn.1673-6184.2008.01.003

2008-01-01

Abstract:Objective To test a novel baculovirus expressing Epstein-Barr virus (EBV) lytic replication immediate early gene Rta,in combination with antiviral chemical ganciclovir,for the activation of latent EBV in nasopharyngeal carcinoma (NPC) cells,and the killing of tumor cells.Methods A baculovirus vector with EBV replication origin OriP,and the Rta expression cassette led by CMV promoter,was used to treat EBV-latently infected NPC cell line Hone1-EBV,as well as nude mice tumor model established from the cell line,in combination with ganciclovir. The effect on the growth of cell and tumor was studied. Results When treated with recombinant baculovirus in combination with ganciclovir,the growth of EBV-positive cells was significantly reduced to only 51% of the control. In the nude mice experiments,tumor growth was also greatly reduced. At 10th day after the first injection,the average volume and weight of the treated group was only about 20% and 30% of that of the control group,respectively. Histological analysis indicated there was significant cell necrosis in the baculovirus-ganciclovir-treated tumor tissue.Conclusion Co-application of Rta-expressing baculovirus vector and ganciclovir may be useful for the therapy of EBV associated NPC.

Minicircle-oriP-IFN Gamma: A Novel Targeted Gene Therapeutic System for EBV Positive Human Nasopharyngeal Carcinoma

The progress of virus-targeted new therapy against Epstein-Barr virus-associated malignancies

Data from Minicircle-IFNγ Induces Antiproliferative and Antitumoral Effects in Human Nasopharyngeal Carcinoma

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models

An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model

Nivolumab Treatment of Relapsed/refractory Epstein-Barr Virus–associated Hemophagocytic Lymphohistiocytosis in Adults

EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules

EBV DNA methylation profiles and its application in distinguishing nasopharyngeal carcinoma and nasal NK/T-cell lymphoma

EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1

Establishment of a protocol for rapidly expanding Epstein-Barr-virus-specific cytotoxic T cells with enhanced cytotoxicity

Identification of HLA-A*11:01 and A*02:01-Restricted EBV Peptides Using HLA Peptidomics

TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.

Adenovirus-mediated Delivery of Interferon-Γ Gene Inhibits the Growth of Nasopharyngeal Carcinoma

Preclinical study of LMP1-RNAi-based anti-tumor therapy in EBV-positive nasopharyngeal carcinoma

Structure-based design of antibodies targeting the EBNA1 DNA-binding domain to block Epstein-Barr virus latent infection and tumor growth

The emerging role of Epstein-Barr virus encoded microRNAs in nasopharyngeal carcinoma

Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody

A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV

A Phase I/II Trial of CRISPR-Cas9-mediated PD-1 Knockout Epstein-Barr Virus Cytotoxic Lymphocytes (Ebv-Ctls) for Advanced Stage EBV Associated Malignancies

Experimental Study on the Co-Application of Rta-expressing Baculovirus Vector and Ganciclovir for the Therapy of Nasopharyngeal Carcinoma

Identification of HLA-A11:01 and A02:01-Restricted EBV Peptides Using HLA Peptidomics